The first experience of the use of two-fraction adaptive intracavitary/interstitial brachytherapy in the treatment of cervical cancer

Abstract

Aim. The study of the results of chemoradiotherapy for cervical cancer with the use of two-fraction brachytherapy.

Methods. The article presents analysis of the examination and treatment results of 17 patients with IIB-IIIB stage cervical cancer. The average age was 51±4.6 years (44 to 62 years). External beam radiotherapy was performed with single boost dose of 1.8 Gy to total dose of 45 Gy. Also the patients received 40 mg/m2 of weekly cisplatin. Intracavitary/interstitial high dose-rate brachytherapy with insertion of parametrial needles consisted of two weekly fractions of 10.0 Gy.

Results. Due to the use of interstitial needles the average dose was 82.2 Gy when recalculated to classical 2 Gy fractions. The median follow up was 16±3,2 months. The used radiotherapy modality for cervical cancer allowed achieving complete tumor involution in 16 (94.1%) patients and partial involution only in 1 (5.9%) case. All females had favorable tolerance and received the entire regimen of planned radiation.

Conclusion. The first experience of the use of concurrent chemoradiotherapy for locally advanced cervical cancer with external beam radiotherapy, two-fraction intracavitary/interstitial adaptive brachytherapy with single boost dose of 10 Gy and 5 weekly infusions of 40 mg/m2 of cisplatin showed high probability of complete and partial tumor response rate with favorable tolerance and acceptable incidence and severity of toxicity.

Keywords

cervical cancer / brachytherapy / chemoradiotherapy / cisplatin

References

[1] Aliev D.A., Isaev I.G., Akperov K.S., Guliev E.G. Results of combined competitive radiotherapy of IIA–IIIB stage cervical cancer patients using intracavitary and interstitial brachytherapy. Voprosy onkologii. 2017; 63 (4): 622–627. (In Russ).

[2] Алиев Д.А., Исаев И.Г., Акперов К.С., Гулиев Э.Г. Результаты сочетанной конкурентной лучевой терапии больных раком шейки матки IIA-IIIB стадий с использованием внутриполостной и внутритканевой брахитерапии. Вопр. онкол. 2017; 63 (4): 622-627.

[3] Aliev D.A., Mardanly F.A., Guliev F.A. et al. Epidemiological aspects of malignant neoplasms in Azerbaijan republic in 2008–2013. Azerbaydzhanskiy zhurnal onkologii i gematologii. 2014; (2): 6–12. (In Russ).

[4] Алиев Д.А., Марданлы Ф.А., Гулиев Ф.А. и др. Эпидемиологические аспекты злокачественных новообразований в Азербайджанской Республике за 2008-2013 гг. Азербайджанский ж. онкол. и гематол. 2014; (2): 6-12.

[5] Aliev D.A., Isaev I.G., Akperov K.S., Guliev E.G. High-dose rate brachytherapy in the treatment of cancer of the cervix uteri. Opukholi zhenskoy reproduktivnoy sistemy. 2011; (2): 89–95. (In Russ).

[6] Алиев Д.А., Исаев И.Г., Акперов К.С., Гулиев Э.Г. Брахитерапия высокой мощностью дозы в лечении рака шейки матки. Опухоли женской репродуктивной системы. 2011; (2): 89-95.

[7] Kozachenko V.P. Cervical cancer. Sovremennaya onkologiya. 2000; 2 (2): 40–44. (In Russ)

[8] Козаченко В.П. Рак шейки матки. Соврем. онкол. 2000; 2 (2): 40-44.

[9] Шакирова Э.Ж., Муллагалиева А.М., Хасанов Р.Ш., Сухорукова Л.К. Меcтно-распространённый рак шейки матки: проблемы диагностики и лечения. Казанский мед. ж. 2007; 88 (6): 627–630. [Shakirova E.Zh., Mullagalieva A.M., Khasanov R.Sh.,

[10] Шакирова Э.Ж., Муллагалиева А.М., Хасанов Р.Ш., Сухорукова Л.К. Меcтно-распространённый рак шейки матки: проблемы диагностики и лечения. Казанский мед. ж. 2007; 88 (6): 627-630.

[11] Sukhorukova L.K. Locally advanced cervical cancer: problems of diagnosis and treatment. Kazanskiy meditsinskiy zhurnal. 2007; 88 (6): 627–630. (In Russ)]

[12] GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr. (access date: 16.10.2017).

[13] GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr. (access date: 16.10.2017).

[14] Fokdal L., Sturdza A., Mazeron R. et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiotherap. Oncol. 2016; 120: 434-440. DOI: 10.1016/j.radonc.2016.03.020.

[15] Fokdal L., Sturdza A., Mazeron R. et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiotherap. Oncol. 2016; 120: 434–440. DOI: 10.1016/j.radonc.2016.03.020.

[16] Han K., Croke J., Foltz W. et al. Prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. Radiotherap. Oncol. 2016; 120: 519-525. DOI: 10.1016/j.radonc.2016.08.002.

[17] Han K., Croke J., Foltz W. et al. Prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. Radiotherap. Oncol. 2016; 120: 519–525. DOI: 10.1016/j.radonc.2016.08.002.

[18] Hanna T., Delaney G., Barton M. The population benefit of radiotherapy for gynaecological cancer: Local control and survival estimates. Radiotherap. Oncol. 2016; 120: 370-377. DOI: 10.1016/j.radonc.2016.04.008.

[19] Hanna T., Delaney G., Barton M. The population benefit of radiotherapy for gynaecological cancer: Local control and survival estimates. Radiotherap. Oncol. 2016; 120: 370–377. DOI: 10.1016/j.radonc.2016.04.008.

[20] Jastaniyah N., Yoshida K., Tanderup K. et al. A volumetric analysis of GTVD and CTVHR as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE). Radiotherap. Oncol. 2016; 120: 404-411. DOI: 10.1016/j.radonc.2016.05.029.

[21] Jastaniyah N., Yoshida K., Tanderup K. et al. A volumetric analysis of GTVD and CTVHR as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE). Radiotherap. Oncol. 2016; 120: 404–411. DOI: 10.1016/j.radonc.2016.05.029.

[22] Minig L., Patrono M., Romero N. et al. Different strategies of treatment for uterine cervical carcinoma stage IB2-IIIB. World J. Clin. Oncol. 2014; 5 (2): 86-92. DOI: 10.5306/wjco.v5.i2.86.

[23] Minig L., Patrono M., Romero N. et al. Different strategies of treatment for uterine cervical carcinoma stage IB2–IIIB. World J. Clin. Oncol. 2014; 5 (2): 86–92. DOI: 10.5306/wjco.v5.i2.86.

[24] Mohamed S., Kallehauge J., Fokdal L. et al. Parametrial boosting in locally advanced cervical cancer: combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy. Brachytherapy. 2015; 14 (1): 23-28. DOI: 10.1016/j.brachy.2014.09.010.

[25] Mohamed S., Kallehauge J., Fokdal L. et al. Parametrial boosting in locally advanced cervical cancer: combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy. Brachytherapy. 2015; 14 (1): 23–28. DOI: 10.1016/j.brachy.2014.09.010.

[26] Ribeiro I., Janssen H., Brabandere M. et al. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients. Radiotherap. Oncol. 2016; 120: 447-454. DOI: 10.1016/j.radonc.2016.04.016.

[27] Ribeiro I., Janssen H., Brabandere M. et al. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients. Radiotherap. Oncol. 2016; 120: 447–454. DOI: 10.1016/j.radonc.2016.04.016.

[28] Soliman A., Elzibak A., Easton H. et al. Quantitative MRI assessment of a novel direction modulated brachytherapy tandem applicator for cervical cancer at 1.5T. Radiotherap. Oncol. 2016; 120: 500-506. DOI: 10.1016/j.radonc.2016.07.006.

[29] Soliman A., Elzibak A., Easton H. et al. Quantitative MRI assessment of a novel direction modulated brachytherapy tandem applicator for cervical cancer at 1.5T. Radiotherap. Oncol. 2016; 120: 500–506. DOI: 10.1016/j.radonc.2016.07.006.

[30] Tanderup K., Fokdal L., Sturdza A. et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiotherap. Oncol. 2016; 120: 441-446. DOI: 10.1016/j.radonc.2016.05.014.

[31] Tanderup K., Fokdal L., Sturdza A. et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiotherap. Oncol. 2016; 120: 441–446. DOI: 10.1016/j.radonc.2016.05.014.

[32] Viswanathan A., Beriwal S., Santos J. et al. The American Brachytherapy Society Treatment Recommendations for locally advanced carcinoma of the cervix. Part II: High dose-rate brachytherapy. Brachytherapy. 2012; 14 (1): 47-52. DOI: 10.1016/j.brachy.2011.07.002.

[33] Viswanathan A., Beriwal S., Santos J. et al. The American Brachytherapy Society Treatment Recommendations for locally advanced carcinoma of the cervix. Part II: High dose-rate brachytherapy. Brachytherapy. 2012; 14 (1): 47–52. DOI: 10.1016/j.brachy.2011.07.002.

[34] Yahya S., Bhatt L., King M. et al. Survival and toxicity following chemoradiation for carcinoma of the cervix - impact of multiple-phase treatment and shielding. Anticancer Res. 2015; 35 (10): 5567-5574. PMID: 26408727.

[35] Yahya S., Bhatt L., King M. et al. Survival and toxicity following chemoradiation for carcinoma of the cervix — impact of multiple-phase treatment and shielding. Anticancer Res. 2015; 35 (10): 5567–5574. PMID: 26408727.

RIGHTS & PERMISSIONS

Isaev I.G., Akperov K.S., Guliev E.G., Alieva N.R., Alieva N.S.